TY - JOUR
T1 - Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer
T2 - a consensus recommendation from the EORTC Imaging and Breast Cancer Groups
AU - Pasquier, David
AU - Bidaut, Luc
AU - Oprea-Lager, Daniela Elena
AU - deSouza, Nandita M.
AU - Krug, David
AU - Collette, Laurence
AU - Kunz, Wolfgang
AU - Belkacemi, Yazid
AU - Bau, Maria Grazia
AU - Caramella, Caroline
AU - de Geus-Oei, Lioe-Fee
AU - de Caluwé, Alex
AU - Deroose, Christophe
AU - Gheysens, Olivier
AU - Herrmann, Ken
AU - Kindts, Isabelle
AU - Kontos, Michalis
AU - Kümmel, Sherko
AU - Linderholm, Barbro
AU - Lopci, Egesta
AU - Meattini, Icro
AU - Smeets, Ann
AU - Kaidar-Person, Orit
AU - Poortmans, Philip
AU - Tsoutsou, Pelagia
AU - Hajjaji, Nawale
AU - Russell, Nicola
AU - Senkus, Elżbieta
AU - Talbot, Jean-Noël
AU - Umutlu, Lale
AU - Vandecaveye, Vincent
AU - Verhoeff, Joost J. C.
AU - van Oordt, Willemien Menke-van der Houven
AU - Zacho, Helle D.
AU - Cardoso, Fatima
AU - Fournier, Laure
AU - van Duijnhoven, Frederieke
AU - Lecouvet, Frédéric E.
N1 - Funding Information: We thank Carine D L Bavelaar-Croon, Béatrice Fournier, Tanja Marinko, Ann Marinus, Evangelia Razis, Sofia Vaz, and Séverine Marchant for their help with copyediting the manuscript. Ann Marinus and Beatrice Fournier organised the logistics of circulating the literature review and Delphi questions and centralising and analysing the answers, along with LC. There was no funding source for this study. Publisher Copyright: © 2023 Elsevier Ltd
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
AB - Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease and clinical trials of oligometastatic breast cancer. After an exhaustive review of the literature covering all aspects of oligometastatic breast cancer, 35 experts from the European Organisation for Research and Treatment of Cancer Imaging and Breast Cancer Groups elaborated a Delphi questionnaire aimed at offering consensus recommendations, including oligometastatic breast cancer definition, optimal diagnostic pathways, and clinical trials required to evaluate the effect of diagnostic imaging strategies and metastasis-directed therapies. The main recommendations are the introduction of modern imaging methods in metastatic screening for an earlier diagnosis of oligometastatic breast cancer and the development of prospective trials also considering the histological and molecular complexity of breast cancer. Strategies for the randomisation of imaging methods and therapeutic approaches in different subsets of patients are also addressed.
UR - http://www.scopus.com/inward/record.url?scp=85166598121&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/S1470-2045(23)00286-3
DO - https://doi.org/10.1016/S1470-2045(23)00286-3
M3 - Review article
C2 - 37541279
SN - 1470-2045
VL - 24
SP - e331-e343
JO - The Lancet Oncology
JF - The Lancet Oncology
IS - 8
ER -